186 related articles for article (PubMed ID: 19297547)
1. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.
Klocek MS; Sassani JW; Donahue RN; McLaughlin PJ; Zagon IS
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5054-61. PubMed ID: 20463323
[TBL] [Abstract][Full Text] [Related]
3. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Zagon IS; Donahue RN; McLaughlin PJ
Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
[TBL] [Abstract][Full Text] [Related]
4. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Biol Cell; 2009 Jan; 20(1):319-27. PubMed ID: 18923142
[TBL] [Abstract][Full Text] [Related]
5. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.
Avella DM; Kimchi ET; Donahue RN; Tagaram HR; McLaughlin PJ; Zagon IS; Staveley-O'Carroll KF
Am J Physiol Regul Integr Comp Physiol; 2010 Feb; 298(2):R459-66. PubMed ID: 19923357
[TBL] [Abstract][Full Text] [Related]
6. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
7. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
[TBL] [Abstract][Full Text] [Related]
8. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
9. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
[TBL] [Abstract][Full Text] [Related]
11. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
Zagon IS; Porterfield NK; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
[TBL] [Abstract][Full Text] [Related]
12. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
13. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
14. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Kren NP; Zagon IS; McLaughlin PJ
Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
[TBL] [Abstract][Full Text] [Related]
17. Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation.
Cheng F; McLaughlin PJ; Banks WA; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2010 Sep; 299(3):R774-85. PubMed ID: 20592180
[TBL] [Abstract][Full Text] [Related]
18. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595
[TBL] [Abstract][Full Text] [Related]
19. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
Qu N; Wang X; Meng Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105723. PubMed ID: 31408839
[TBL] [Abstract][Full Text] [Related]
20. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]